Swedish Orphan Biovitrum AB (publ) : Invitation - Presentation of Sobi's first
quarter results 2013
On April 26, at 08:00 CET, Swedish Orphan Biovitrum AB (Sobi) will publish its
interim report for the first quarter, 2013.
Financial analysts and media are invited to participate in a telephone
conference, which will include a presentation of the results, at 14:00 CET.
The event will be hosted by Sobi's CEO and President, Geoffrey McDonough, and
the presentation will be held in English.
The presentation can be followed live or afterwards on our website,
www.sobi.com. Slides used in the presentation will be made available on our
website prior to the telephone conference.
To participate in the telephone conference, please call:
SE: +46 8 5199 9366
US: +1877788 9023
UK: +44207660 2078
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within hemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi
is a pioneer in biotechnology with world-class capabilities in protein
biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of
SEK 1.9 billion (€ 215 M) and about 480 employees. The share (STO: SOBI) is
listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com
For more information - not for publication
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor
T: +46 70410 71 80 T: +46 8 697 20 00
Sobi press release April 17, 2013 in pdf version
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.